Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression

European Journal of Clinical Investigation

Volumn 41, Issue 11, 2011, Pages 1164-1171

  Morris Rosenfeld, Samuel ^a   Blessing, Erwin ^a   Preusch, Michael R ^a   Albrecht, Claudia ^a   Bierhaus, Angelika ^a   Andrassy, Martin ^a   Nawroth, Peter P ^a   Rosenfeld, Michael E ^b   Katus, Hugo A ^a   Bea, Florian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Bone marrow transplantation; Macrophages; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; APOLIPOPROTEIN E; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BRACHIOCEPHALIC TRUNK; CELL INFILTRATION; CHIMERA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW; BONE MARROW TRANSPLANTATION; CHEMOKINE CCL2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80053924397     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02514.x     Document Type: Article

References (34)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007;219:187-203.
3. Brett J, Schmidt AM, Yan SD, Zou SY, Weidman E, Pinsky D et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Path 1993;143:1699-712.
4. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
5. Moser B, Desai DD, Downie MP, Chen Y, Yan SF, Herold K et al. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol 2007;179:8051-8.
6. Kokkola R, Anderssony Å, Mullinsz G, Östberg T, Treutigerz CJ, Arnold B et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61:1-9.
7. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008;11:91-9.
8. Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205:275-85.
9. Isoda K, Folco E, Marwali RM, Ohsuzu F, Libby P. Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis. Atherosclerosis 2008;198:307-12.
10. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005;25:1401-7.
11. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-35.
12. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006;185:70-7.
13. Bro S, Flyvbjerg A, Binder CJ, Bang CA, Denner L, Olgaard K et al. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis 2008;201:274-80.
14. Figarola JL, Shanmugam N, Natarajan R, Rahbar R. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 2007;56:647-55.
15. Soro-Paavonen A, Watson A, Li J, Paavonen K, Koitka A, Calkin AC et al. RAGE deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-9.
16. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008;118:183-94.
17. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the apoE knockout mouse. Arterioscler Thromb Vasc Biol 2000;20:2587-92.
18. Blessing E, Preusch M, Kranzhoefer R, Kinscherf R, Marx N, Rosenfeld ME et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis 2008;199:295-303.
19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
20. Xu Y, Arai H, Murayama T, Kita T, Yokode M. Hypercholesterolemia contributes to the development of atherosclerosis and vascular remodeling by recruiting bone marrow-derived cells in cuff-induced vascular injury. Biochem Biophys Res Commun 2007;363:782-7.
21. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995;267:1034-7.
22. Van Eck M, Herijgers N, Vidgeon-Hart M, Pearce NJ, Hoogerbrugge PM, Groot PHE et al. Accelerated atherosclerosis in C57Bl:6 mice transplanted with ApoE-deficient bone marrow. Atherosclerosis 2000;150:71-80.
23. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003;108:1917-23.
24. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003;98:1507-15.
25. Yeh CH, Sturgis L, Haidacher L, Zhang XN, Sherwood SJ, Bjercke RJ et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kB transcriptional activation and cytokine secretion. Diabetes 2001;50:1495-504.
26. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:19919-24.
27. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kB. Diabetes 2001;50:2792-808.
28. Barnes PJ, Karin M. Nuclear Factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
29. Peng D, Hiipakka RA, Reardon CA, Getz GS, Liao S. Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver receptor agonist T0901317. Atheroscerosis 2009;203:59-66.
30. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 2004;24:12-22.
31. Reardon CA, Getz GS. Mouse models of atherosclerosis. Curr Opin Lipidol 2001;12:167-73.
32. Jackson CL. Defining and defending murine models of plaque rupture. Arterioscler Thromb Vasc Biol 2007;27:973-7.
33. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7.
34. Hristov M, Zernecke A, Schober A, Weber C. Adult progenitor cells in vascular remodeling during atherosclerosis. Biol Chem 2008;389:837-44.